Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07498335 · ClinicalTrials.gov registry record · Phase 3
Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Atrasentan in Pediatric Patients With Primary IgAN
A Phase 3 study, sponsored by Novartis Pharmaceuticals.
- Not yet
- Registry status
- Phase 3
- Development phase
- 28
- Enrollment target
NCT07498335 is a Phase 3 study that has not yet begun recruiting, run by Novartis Pharmaceuticals. The registered enrollment target is 28 participants.
The verdict
NCT07498335, a Phase 3 study, has not yet begun recruiting, sponsored by Novartis Pharmaceuticals.
- NOT YET RECRUITING
- Registry status
- Phase 3
- Development phase
- 28 participants
- Enrollment target
Study Summary
A Phase III, single-arm, multicenter pediatric clinical study evaluating atrasentan in children and adolescents aged 2 to \<18 years with primary immunoglobulin A nephropathy (IgAN).
Interventions
- DRUG Drug: Atrasentan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2026-08-26 |
| Est. Completion | 2032-12-13 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07498335
The ClinicalTrials.gov registry entry for NCT07498335 describes a study currently listed as not yet recruiting, categorized as Phase 3. The registered enrollment target is 28 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Drug: Atrasentan is the first listed.
NCT07498335 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07498335 about?
NCT07498335 is a clinical study titled "Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Atrasentan in Pediatric Patients With Primary IgAN". A Phase III, single-arm, multicenter pediatric clinical study evaluating atrasentan in children and adolescents aged 2 to \<18 years with primary immunoglobulin A nephropathy (IgAN).
What is the current status of trial NCT07498335?
This trial is currently not yet recruiting. It is a Phase 3 study. The enrollment target is 28 participants. The study started on 2026-08-26. Estimated completion is 2032-12-13.
What interventions are being tested in trial NCT07498335?
The interventions under investigation include: Drug: Atrasentan (DRUG).
Who is sponsoring clinical trial NCT07498335?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.